US-based Gilead Sciences has roped in four Indian pharmaceutical companies to develop and market three new generic HIV/AIDS drugs in over 100 countries. The drugs are currently in final stages of clinical development. CNBC-TV18's Appaji Reddem and Ashwin Mohan delve deeper.